NASH Drug Development: Experts Argue The Case For Noninvasive Tests As Surrogate Endpoints For Approval

Cairns
An FDA official cautioned against trying to build a surrogate on a surrogate. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards